A recent study performed by Sun et al. (111) showed that MEOX1 (mesenchyme homeobox 1) may be a novel target in BCSCs of PTEN-deficient trastuzumab-resistant breast cancers. This evidence concerns the gene MEOX1 and breast carcinoma.